FDA set to rule on legal compounding of peptides including BPC-157 and TB-500

The U.S. Food and Drug Administration is set to decide whether seven peptides, including BPC-157 and TB-500, can be legally compounded, which would potentially open the door to broader availability across the United States. The ruling could significantly reshape the market for compounded medications and dietary supplements. The outcome will determine whether these substances can be prescribed and prepared legally by compounding pharmacies.

More on this topic

🏥 Health FDA Advisory Panel Votes to Allow Compounding of Peptides BPC-157 and KPV STAT News · 1h ago 🏥 Health FDA Advisory Panel Weighs Easing Access Restrictions on Seven Peptides NPR Health · 12h ago 🏥 Health FDA appoints peptide-promoting physicians to panel advising on peptide rules STAT News · 24d ago 🏥 Health FDA reports 72-case Cyclospora outbreak — sixth of the year amid record US surge Ars Technica · 1h ago 🏥 Health FDA Eyes Approval of Unproven Peptide Injections Backed by RFK Jr. as Scientists Warn of Risks The Independent World · 5h ago 🏥 Health FDA Weighs Peptide Decision; Merck Ebola Vaccine Shows Promise in DRC Outbreak STAT News · 6h ago